Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanomaLisa Haas, Anna C. Obenauf, Izabela Kręcioch et al.|Nature Cancer|2021Cited by 196
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responsesFelix Bayerl, Jan P. Böttcher, Philippa Meiser et al.|Immunity|2023Cited by 176
Cancer cells impair monocyte-mediated T cell stimulation to evade immunityAnais Elewaut, Anna C. Obenauf, Guillem Estivill et al.|Nature|2024Cited by 122